ALAUNOS THERAPEUTICS INC (TCRT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.84+2.22%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · TCRT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 754.5% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
TCRT — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-10-21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Background As previously disclosed, on April 9, 2026, Alaunos Therapeutics, Inc. (the “Company”) received a written notice (the “Deficiency Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Marke…
Why it matters: The new pipeline has no human trial data. IND filings would mark a move from lab work toward clinical testing.
Supportive ifThe company files IND or CTA applications for VLR199 and VLR360 by the stated second half of 2027.
Worry ifNeither filing appears by year-end 2027. The company reports a delay or regulatory hold.
Why it matters: The October deal raised large sums but also created many preferred shares. A vote will clarify whether they can convert into common shares.
Watch forStockholders approve the Series C conversion plan. A filing lists the terms and share count.
Also watch forStockholders reject the conversion plan, or the company delays the vote without setting a new date.
Why it matters: The liver finding came from a small, non-GLP mouse study. A controlled repeat would test if that result holds up.
Supportive ifA controlled follow-up study finds lower liver weight after adjusting for body fat. It states the group size and test method.
Worry ifA controlled follow-up finds no drop in liver weight after adjustment. Or it reports safety concerns that stop the work.
Why it matters: Nasdaq cited a stockholders' equity shortfall. A decision or new deadline will show whether listing risk remains.
Watch forA Nasdaq filing confirms TCRT meets the $2.5 million equity rule or grants more time to comply.
Also watch forNasdaq says TCRT failed to meet the rule and sets a delisting date.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$306 on $10,000 · ±3.1% | How much price usually moves either way. |
| Bad day | $980 loss on $10,000 · 9.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,297 loss on $10,000 · 83.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.